Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

PARP inhibitors in metastatic breast cancer: The present and the future

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 23.10.19
Views: 1013

Elahe Salehi - Dana-Farber Cancer Institute, Boston, USA

Elahe Salehi speaks to ecancer at the APAO 2019 meeting in Boston about the use of PARP inhibitors in metastatic breast cancer.

She explains that these agents are typically used upfront in patients who are positive for the BRCA mutation and specifies that olaparib is the main agent used in the clinic.

Salehi discusses the tolerability of this drug and some of the side effects associated with this type of therapy - especially with patients who have undergone multiple rounds of chemotherapy.

She concludes by outlining the future for PARP inhibitors in this disease setting - including the use of these agents in combination with other types of therapy and after platinum-based chemotherapy.

This programme has been supported by an unrestricted educational grant from Pfizer.

Related videos

follow us

SIOG metastatic renal cell carcinoma

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation